Dr. Virginia Kaklamani highlights the EMBER-3 clinical trial, which found that imlunestrant outperformed single-agent endocrine therapy in patients with ESR1 mutations and showed improvement when combined with abemaciclib, suggesting potential FDA approval.
00:00 - EMBER-3 clinical trial results
00:58 - Combination therapy findings